⚡ StockFin Pro Unlimited AI queries. No ads. Full research access. View Plans → Ad

Shilpa Medicare Limited (SHILPAMED) — Announcement

· NSE Neutral

Shilpa Medicare announced a strategic equity partnership where its subsidiary Shilpa Biocare will acquire a 30.4% stake in Spanish biotech Gate2Brain for a total contribution of €7 million, including €0.5 million cash, €5.5 million for services, and €1 million for development. The partnership grants Shilpa a controlling interest to advance Gate2Brain's lead oncology candidate G2B-002, which targets pediatric brain cancers like DIPG and glioblastoma and has received orphan drug designations from both the U.S. FDA and EMA. The deal positions Shilpa in a high-growth oncology market projected to exceed $6 billion by 2035 while expanding its CDMO capabilities in neuroscience therapeutics.

📄 View Original Announcement (PDF)

⚡ StockFin Pro Unlimited AI queries. No ads. Full research access. View Plans → Ad
📊 Stock Analysis — SHILPAMED ✨ Ask AI About This

About Shilpa Medicare Limited (SHILPAMED)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹9,356.63 Cr P/E: 106.1

View full SHILPAMED stock details →

📡 Get AI alerts when SHILPAMED files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SHILPAMED — Free

💡 Ask AI about this filing

Ask AI Free →

📊 More SHILPAMED filings

See all SHILPAMED filings →

🔥 Also filed on 3 June 2026

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

📡 Get AI alerts when SHILPAMED files new disclosures

Track SHILPAMED filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track SHILPAMED — Free

Free account · 2 AI queries/day

⚡ StockFin Pro Go Pro — Unlimited queries, no ads Upgrade Ad

© 2026 StockFin.ai — AI-powered Indian stock research

Today's Announcements · Screener · Insights · AI Chat